Disulfide Cross-Linked Micelles for the Targeted Delivery of Vincristine to B-Cell Lymphoma
Authors:
- 1 May 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 9 (6) , 1727-1735
Abstract
Vincristine (VCR) is a potent anticancer drug, but its clinical efficacy is limited by neurotoxicity. The field of drug delivery may provide an opportunity to increase the therapeutic index of VCR by delivering the drug specifically to tumor sites while sparing normal tissue. We have recently developed a telodendrimer (PEG5k-Cys4-L8-CA8) capable of forming disulfide cross-linked micelles (DCMs) which can encapsulate a variety of chemotherapeutics. In the present study, we encapsulated VCR into these micelles (DCM-VCR) and used them to treat lymphoma bearing mice. DCM-VCR particles have a size of 16 nm, which has been shown to be optimal for their accumulation into tumor via the enhanced permeability and retention (EPR) effect. Compared to our first-generation non-cross-linked micelles (NCMs), DCM-VCR demonstrated greater stability and slower drug release under physiological conditions. In addition, DCM-VCR exhibited a maximum tolerated dose (MTD) of 3.5 mg/kg while the MTD for conventional VCR was only 1.5 mg/kg. Using a near-infrared cyanine dye (DiD) as the surrogate drug, we showed that DCM-VCR accumulated at the tumor site starting 1 h after injection and persisted up to 72 h in lymphoma xenografted nude mice. In an in vivo efficacy study, high dose (2.5 mg/kg) DCM-VCR produced the greatest reduction in tumor volume. High dose DCM-VCR was well tolerated with no significant changes in complete blood count, serum chemistry and histology of the sciatic nerve. Mice treated with an equivalent dose (1 mg/kg) of conventional VCR and DCM-VCR controlled tumor growth equally; however, in combination with on-demand addition of the reducing agent N-acetylcysteine, DCM-VCR exhibited a superior antitumor effect compared to conventional VCR.Keywords
This publication has 30 references indexed in Scilit:
- Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel deliveryBiomaterials, 2011
- The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticlesBiomaterials, 2011
- A novel size-tunable nanocarrier system for targeted anticancer drug deliveryJournal of Controlled Release, 2010
- Well-Defined, Size-Tunable, Multifunctional Micelles for Efficient Paclitaxel Delivery for Cancer TreatmentBioconjugate Chemistry, 2010
- A self-assembling nanoparticle for paclitaxel delivery in ovarian cancerBiomaterials, 2009
- Vincristine: Can its therapeutic index be enhanced?Pediatric Blood & Cancer, 2009
- Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphomaCancer, 2009
- Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastineCancer Chemotherapy and Pharmacology, 2009
- Heterozygous P0 deficiency protects mice from vincristine‐induced polyneuropathyJournal of Neuroscience Research, 2006
- An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal modelsToxicology Letters, 2001